To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company plans to use an ...
In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...
Jamie Dimon is right to be alarmed about our national-security vulnerabilities, especially an overreliance on China and India for generic prescription drugs (“Investments for National Security,” op-ed ...
Against a backdrop of tariff updates and a drug pricing deal from the Trump administration, the FDA charted a pair of moves this week in its push to make drug manufacturing more attractive in the U.S.
US Securities and Exchange Commission Chair Paul Atkins says the new listing standards will reduce barriers to access digital asset products and give investors more choice. ”This approval helps to ...
The settlement agreement will extend market exclusivity for AbbVie’s JAK inhibitor in the U.S. until 2037—providing pediatric exclusivity is granted. AbbVie has reached a settlement with generic ...
BlackLine has ambitions to automate the Office of the CFO with AI, but not of the "generic dangerous" variety, says CTO Jeremy Ung. AI on its own isn't the product. Thank you Owen Ryan, co-CEO at ERP ...
NEW YORK, Sept 2 (Reuters) - Some Chinese companies now racing to make generic versions of Novo Nordisk's (NOVOb.CO), opens new tab Wegovy also supplied ingredients for more than a billion makeshift ...
Medications are rarely made from start to finish in a single country; raw materials, active ingredients and final products often cross multiple borders before reaching patients in the U.S., The New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results